Risperidone has been found to be useful in the treatment of acute bipolar disorders. This is a case report where risperidone mono therapy has been found to be effective in prophylaxis of bipolar affective disorder. The pharmacological and clinical implications of risperidone in the management of BPAD are discussed
Introduction
Since the introduction of serotonin dopamine antagonists in psychiatry their role in the management of Bipolar Affective Disorder (BPAD) have been of immense interest Recently risperidone has been approved for the treatment of BPAD by FDA. The earlier studies about the role of atypical antipsychotics in BPAD are inconclusive. Dwight et al., (1994) and Lane et al., (1940) reported emergence of manic symptoms with risperidone and Tohen et al., (1999) found that olanzapine was helpful in mixed episodes of BPAD when used in combination with sodium valproate or lithium carbonate. Most of the recent studies found that risperidone is useful in the management of acute bipolar-mania when used alone (Khanna et al., 2003) and also when used in combination with a mood stabilizer (Sachs et al., 2002) .No data are available regarding the role of risperidone mono therapy in maintenance treatment of BPAD. We are reporting here a case where risperidone mono therapy is found to be effective in the maintenance treatment of BPAD.
Case Report
Mr. J.L. is a 35 year old unmarried male from lower socioeconomic class. He was diagnosed to have mixed affective episode in 1992 and was treated with Lithium 1200mg. The patient recovered . However , he stopped Lithium after four months. He had the second episode in 1996 which was diagnosed as BPAD -mania. He was treated with Lithium 1200mg, Trifluperazine 10mg and Chlorpromazine 50mg. Though the first episode was mixed, patient had responded well to Lithium. So Lithium was the natural choice in the second episode. Moreover, his episode was a Manic episode. Patient had two episodes in 1997 while he was on 1000mg of Lithium as the maintenance therapy. After his fifth episode in 1998 , Carbamazepine 600mg was added to 1000mg of Lithium as the maintenance therapy. Despite that the patient had another episode in January 1999 during which both lithium and carbamazipine were tapered and sodium valproate was started and maintained at a dose of 1500mg. He had another manic episode in Oct. 99 during which risperidone eight milligram was added to 1500mg of sodium valproate. He stopped sodium valproate by himself(for financial reasons) during the maintenance phase and continued taking four milligram of risperidone. There was no history of substance use or presence of any psychosocial stressors during the period (1996 -1999) in which the patient had experienced frequent episodes. He started working as a driver and was able to continue working for an uninterrupted period of three years since his second episode in 1996. He had only manic and mixed episodes during the course of illness. All the episodes were severe enough to warrant inpatient treatment. Though the patient was euthymic without medication from 1992 to 1996 ( four years) he had five episodes between 1996 and 1999. So it is very unlikely that the euthymic period between 1999 and 2003 during which he was on Risperidone was a natural remission. He was brought to the hospital in November 2003 with irritability, decreased need for sleep, increased libido, increased religiosity, aggressive behaviour, suspiciousness, decreased need for sleep, feeling of worthlessness, recurrent thoughts of death. Mental status examination revealed increased psychomotor activity, disinhibited behaviour, overfamilarity, grandiose ideas, distractibility and mood disturbance changing from elation to crying spells within the same day. Risperidone was increased to eight milligrams, carbamazepine was started and gradually increased to 1200mg and 300 mg of chlorpromazine was added. Currently all other medications apart from Risperidone have been withdrawn and the patient is on Risperidone in the maintenance phase.
Discussion
Risperidone , a benzisoxazole derivative binds with high affinity to serotonin type 2(5HT2)receptors, dopamine D2 receptors and alpha adrenergic receptors. Risperidone binds with lower affinity to the alpha 2 adrenergic receptors but it does not bind to dopamine D1 or muscarinic cholinergic receptors The emergence of manic symptoms with risperidone was reported by Lane et al (1998) in which he hypothesized that manic symptoms may be due to function of ratio of 5HT2A receptors occupancy with respect to D2 receptors occupancy. Similar findings have been reported by Lidenmayer and Klebanov(1998) and John et al (1998) . But Sachs et al (2002) found that addition of risperidone to a mood stabilizer was a safe therapy and was more effective in treatment of acute bipolar mania .They reported the severity of manic symptoms , chances of breakthrough manic and mixed affective episodes, and Young Mania Rating Scale (YMRS) total score at endpoint were significantly lower in patients receiving a mood stabilizer and risperidone than patients receiving a mood stabilizer and a placebo. Khanna et al(2003) found that risperidone mono therapy is effective in treatment of acute bipolar mania and efficacy was seen at all time points starting with week one and was sustained to treatment end point. They also reported that antimanic activity of risperidone was independent of presence or absence of psychotic features and that the treatment was safe and generally well tolerated. Though clinicians have tried maintaining Bipolar disorder patients on various typical antipsychotics, no control studies were done in this field.
Moreover due to the higher chances of Tardive Dyskinesia in Bipolar disorder patients, use of long term typical antipsychotics are not encouraged in the maintenance treatment of bipolar disorder. So far there are no studies or case reports available about the role of risperidone mono therapy in maintenance phase of BPAD. A single case report like this is only of heuristic value. However we believe that this case is unusually clear as the patient had interepisodic full remission while he was maintained only on risperidone. A mood stabilizer has been defined as a "a drug that alleviates the frequency, intensity, or both of manic, hypomanic, depressive, or mixed episodes in patients of bipolar disorder and that does not increase frequency or severity of any phase of bipolar disorder" (Bowden CL,1997) . Though in this case risperidone is found to act like a mood stabilizer we need randomized controlled studies for a definite conclusion.
